#	Pagina
attuale pagina	/open-fp7/projects/105662/index.html

HEMIBIO

HEPATIC MICROFLUIDIC BIOREACTOR

Coordinatore	KATHOLIEKE UNIVERSITEIT LEUVEN Organization address address: Oude Markt 13 city: LEUVEN postcode: 3000 contact info Titolo: Dr. Nome: Elke Cognome: Lammertyn Email: send email Telefono: +32 16 32 06 21 Fax: +32 16 32 65 15
Nazionalità Coordinatore	Belgium [BE]
Totale costo	9˙400˙000 €
EC contributo	4˙700˙000 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2010-Alternative-Testing
Funding Scheme	CP-IP
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-01-01 - 2015-12-31

Partecipanti

#	participant	country	role	EC contrib. [€]
1	KATHOLIEKE UNIVERSITEIT LEUVEN Organization address address: Oude Markt 13 city: LEUVEN postcode: 3000 contact info Titolo: Dr. Nome: Elke Cognome: Lammertyn Email: send email Telefono: +32 16 32 06 21 Fax: +32 16 32 65 15	BE (LEUVEN)	coordinator	785˙300.80
2	VRIJE UNIVERSITEIT BRUSSEL Organization address address: PLEINLAAN 2 city: BRUSSEL postcode: 1050 contact info Titolo: Ms. Nome: Maria Cognome: Vereeken Email: send email Telefono: +32 2 6293808 Fax: +32 2 6293640	BE (BRUSSEL)	participant	583˙181.25
3	THE HEBREW UNIVERSITY OF JERUSALEM. Organization address address: GIVAT RAM CAMPUS city: JERUSALEM postcode: 91904 contact info Titolo: Ms. Nome: Jane Cognome: Turner Email: send email Telefono: +972 2 6586676 Fax: +972 2 6513205	IL (JERUSALEM)	participant	477˙426.00
4	FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V Organization address address: Hansastrasse 27C city: MUENCHEN postcode: 80686 contact info Titolo: Ms. Nome: Andrea Cognome: Zeumann Email: send email Telefono: +49 89 1205 2723 Fax: +49 89 1205 7534	DE (MUENCHEN)	participant	471˙533.62
5	INSERM - TRANSFERT SA Organization address address: Rue Watt 7 city: PARIS postcode: 75013 contact info Titolo: Mr. Nome: Louis Cognome: Jammayrac Email: send email Telefono: +33 1 55030101 Fax: +33 1 55030160	FR (PARIS)	participant	413˙878.34
6	MEDICYTE GMBH Organization address address: Im Neuenheimer Feld 581 city: Heidelberg postcode: 69120 contact info Titolo: Mr. Nome: Stefan Cognome: Holder Email: send email Telefono: +49 6221 72925 33 Fax: +49 6221 72925 31	DE (Heidelberg)	participant	287˙734.00
7	INTERUNIVERSITAIR MICRO-ELECTRONICA CENTRUM VZW Organization address address: Kapeldreef 75 city: LEUVEN postcode: 3001 contact info Titolo: Ms. Nome: Christine Cognome: Van Houtven Email: send email Telefono: +32 16 281 613 Fax: +32 16 281 812	BE (LEUVEN)	participant	283˙237.66
8	CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECHNIQUE SA - RECHERCHE ET DEVELOPPEMENT Organization address address: RUE JAQUET DROZ 1 city: NEUCHATEL postcode: 2007 contact info Titolo: Dr. Nome: Olivier Cognome: Guenat Email: send email Telefono: +41 81 307 8130 Fax: +41 81 307 8100	CH (NEUCHATEL)	participant	282˙953.62
9	UNIVERSITETET I TROMSOE Organization address address: Hansine Hansens veg 14 city: TROMSO postcode: 9037 contact info Titolo: Mr. Nome: ørjan Cognome: Olsen Email: send email Telefono: +47 77 623267 Fax: +47 77 645300	NO (TROMSO)	participant	281˙749.56
10	UNIVERSITETET I OSLO Organization address address: Problemveien 5-7 city: OSLO postcode: 313 contact info Titolo: Ms. Nome: Eva Helene Cognome: Mjelde Email: send email Telefono: +47 228 51180 Fax: +47 228 51493	NO (OSLO)	participant	279˙561.30
11	CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER Organization address address: CALLE ROSSELLO 149 PUERTA BJS city: BARCELONA postcode: 8036 contact info Titolo: Ms. Nome: Pastora Cognome: Martinez Samper Email: send email Telefono: +34 93 227 5707 Fax: +34 93 227 9205	ES (BARCELONA)	participant	276˙801.80
12	UNIVERSITAETSKLINIKUM FREIBURG Organization address address: HUGSTETTER STRASSE 49 city: FREIBURG postcode: 79106 contact info Titolo: Mr. Nome: Juergen Cognome: Dreyer Email: send email Telefono: +49 761 270 20810 Fax: +49 761 270 18890	DE (FREIBURG)	participant	188˙873.38
13	MEDIZINISCHE HOCHSCHULE HANNOVER Organization address address: Carl-Neuberg-Strasse 1 city: HANNOVER postcode: 30625 contact info Titolo: Mr. Nome: Frank Cognome: Dittrich Email: send email Telefono: +49 511 532 5343 Fax: +49 511 532 4253	DE (HANNOVER)	participant	87˙768.62

Mappa

Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

compounds dose human bioreactor hepatotoxicity sensors cells hsec hepatic functional device microfluidic reactors toxicity ipsc repeated hepatocytes cell liver cellular hsc

Obiettivo del progetto (Objective)

'The goal of HeMiBio is to develop a hepatic microfluidic bioreactor from human iPSC-derived hepatocytes, hepatic sinusoidal endothelial cells (HSEC) and stellate cells (HSC), suitable for inclusion in a repeated dose toxicity testing strategy of pharmaceuticals/cosmetic ingredients. The successful creation of such a liver-device requires (a) homotypic and heterotypic interactions between the three cell types to induce and maintain their functional, differentiated state, and (b) optimisation of the matrix, oxygenation conditions, nutrient transport and physiological shear forces. The objectives are (1) to engineer the cellular components incorporated in the bioreactor to enable specific and spatially defined enrichment of the different cells from iPSC progeny, and, by gene editing, to allow non-invasive monitoring of the cellular state (differentiation and damage). (2) Aside from the molecular sensors, an array of electro-chemical sensors will be embedded in the reactors to assess liver-specific function and cellular health under repeated dose toxicity conditions, dynamically and in a high-throughput way. Cells and sensors will be built into (3) bioreactors that will be sequentially upgraded from 2D to 3D microfluidic reactors to ultimately allow full maintenance of mature functional hepatocytes, HSC and HSEC for >28 days. (4) As the ultimate goal is to use the device as a human-based alternative to rodent long-term hepatotoxicity studies, it will be of utmost importance to provide proof of concept that the 3D-devices reveal the hepatotoxicity of prototypical hepatotoxic compounds in vivo (5). “-Omics” and cell functionality studies will provide evidence that liver-like cells are present, exposed and affected by the selected toxic compounds. These ambitious objectives will be achieved by the excellent project team, composed of academic/industrial partners with unique and complementary biology, physiology, toxicology and technical skills from 7 EU Member States.'

Introduzione (Teaser)

Replacing animals in toxicity testing is important for the biotechnology, pharmaceutical and cosmetics industries. There is a need for new human cell models, due to the often poor correlation between animal and human toxicity testing.